12:00 AM
Apr 13, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SBG: Completed Phase III enrollment

Biotec Pharmacon completed enrollment of 130 patients in a double-blind, placebo-controlled, international Phase III trial (SGB-1-13) evaluating topical SBG for up to...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >